ClinicalTrials.gg
CompletedNCT06140290Updated Mar 24, 2025Results posted

A Sub Study to Evaluate the Study Medication (Etrasimod) Using Wearable Sensors in Healthy Participants

A Phase 1 interventional study of Etrasimod Immediate Release (IR) in Healthy Participants, sponsored by Pfizer. Completed at 1 site in Belgium. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-24.

Sponsored by Pfizer · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to look at how healthy adults process Etrasimod when assessed by wearable sensors. Etrasimod is taken without food and assessments taken by site staff and then by participants after training.

The study is seeking participants who are:

  • Aged 18 or older
  • Male or female who are healthy as determined by medical assessment
  • Body-mass index (BMI) of 16 to 32, and a total body weight > 50kg.

The study will take up to 9 weeks, including the screening period. Participants will have to stay at the study clinic for at least 2 nights, in each of 2 study periods.

Participants will take Etrasimod as a tablet by mouth without food. Blood samples will be taken both before and after participants take Etrasimod. Participants will also use wearable devices to assess blood pressure, heart rate and take further blood samples. A follow-up phone call will be made 20 to 27 days after the last study period.

02

Conditions studied

  • Healthy Participants

Keywords

  • etrasimod
  • adults
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy participants
  • 16 to 32 kg/m2
  • body weight more than 50kg

Exclusion criteria

Exclusion Criteria:

  • Ongoing or past history of significant medical conditions
  • Eye disorders such as macular edema or uveitis
  • Ongoing or recent infections
  • Use of prescription or non prescription medications within 7 days of first dose
  • Smoking or using nicotine products equivalent to more than 5 cigarettes per day
  • History of severe allergic or anaphylactic reactions
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    Fixed Sequence

    Single oral dose of etrasimod 2mg tablet under fasted conditions with site staff led assessments and training on how to use wearable sensors followed by single oral dose 2mg tablet under fasted conditions with participant led assessments with wearable sensors.

    Drug: Etrasimod Immediate Release (IR)

Interventions

  • DrugEtrasimod Immediate Release (IR)

    An immediate release tablet

06

What researchers measure

Primary outcomes

  1. Area Under the Serum Concentration-Time Profile From Time Zero to 24 Hours (AUC0-24) of Etrasimod: Tasso PK Sampling

    AUC0-24 was calculated as linear/log trapezoidal method. PK sampling: a) Treatment F/Reference: Tasso PK micro sampling was done by clinical research unit (CRU) staff participants at the CRU up to 24 hours post-dose and by participants 48-168 hours post-dose remotely; b) Treatment G/Test: Tasso PK micro sampling was done by participants at the CRU up to 24 hours post-dose and 48-168 hours post-dose remotely.

    Time frame: Pre-dose (0 hour), 1, 2, 4, 6, 8, 12 and 24 hours post-dose on Day 1 of each period

  2. Area Under the Serum Concentration-Time Profile From Time 24 Hours to the Time of the Last Quantifiable Concentration (AUC24hr-last) of Etrasimod: Tasso PK Sampling

    AUC24hr-last was calculated as linear/log trapezoidal method. PK sampling: a) Treatment F/Reference: Tasso PK micro sampling was done by CRU staff participants at the CRU up to 24 hours post-dose and by participants 48-168 hours post-dose remotely; b) Treatment G/Test: Tasso PK micro sampling was done by participants at the CRU up to 24 hours post-dose and 48-168 hours post-dose remotely.

    Time frame: 24, 48, 72, 96, 120, 144, and 168 hours post-dose on Day 1 of each period

  3. Area Under the Serum Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUCinf) of Etrasimod: Tasso PK Sampling

    AUCinf was calculated as AUClast + (Clast\*/kel), where AUClast is area under the plasma concentration-time profile from time zero to the time of the last quantifiable concentration (Clast). Clast is the predicted plasma concentration at the last quantifiable time point and Kel is the terminal phase rate constant. PK sampling: a) Treatment F/Reference: Tasso PK micro sampling was done by CRU staff participants at the CRU up to 24 hours post-dose and by participants 48-168 hours post-dose remotely; b) Treatment G/Test: Tasso PK micro sampling was done by participants at the CRU up to 24 hours post-dose and 48-168 hours post-dose remotely.

    Time frame: Pre-dose (0 hour), 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours post-dose on Day 1 of each period

  4. Maximum Observed Concentration (Cmax) of Etrasimod: Tasso PK Sampling

    PK sampling: a) Treatment F/Reference: Tasso PK micro sampling was done by CRU staff participants at the CRU up to 24 hours post-dose and by participants 48-168 hours post-dose remotely; b) Treatment G/Test: Tasso PK micro sampling was done by participants at the CRU up to 24 hours post-dose and 48-168 hours post-dose remotely.

    Time frame: Pre-dose (0 hour), 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours post-dose on Day 1 of each period

Secondary outcomes

  1. AUC0-24 of Etrasimod: Tasso and Venous PK Sampling

    AUC0-24 was calculated as linear/log trapezoidal method. In this outcome measure, as planned, data of participants who received Etrasimod 2 mg IR tablet (Treatment A) in C5041034 study is used for comparison. PK sampling: a) Treatment F/Test: Tasso PK micro sampling was done by CRU staff participants at the CRU up to 24 hours post-dose and by participants 48-168 hours post-dose remotely; b) Treatment G/Test: Tasso PK micro sampling was done by participants at the CRU up to 24 hours post-dose and 48-168 hours post-dose remotely; c) Treatment A/Reference: Venous PK sampling from pre-dose (0 hour) till 168 hours post-dose.

    Time frame: Pre-dose (0 hour), 1, 2, 4, 6, 8, 12 and 24 hours post-dose on Day 1 of each period

  2. AUC24hr-last of Etrasimod: Tasso and Venous PK Sampling

    AUC24hr-last was calculated as linear/log trapezoidal method. In this outcome measure, as planned, data of participants who received Etrasimod 2 mg IR tablet (Treatment A) in C5041034 study is used for comparison. PK sampling: a) Treatment F/Test: Tasso PK micro sampling was done by CRU staff participants at the CRU up to 24 hours post-dose and by participants 48-168 hours post-dose remotely; b) Treatment G/Test: Tasso PK micro sampling was done by participants at the CRU up to 24 hours post-dose and 48-168 hours post-dose remotely; c) Treatment A/Reference: Venous PK sampling from pre-dose (0 hour) till 168 hours post-dose.

    Time frame: 24, 48, 72, 96, 120, 144, and 168 hours post-dose on Day 1 of each period

  3. AUCinf for Etrasimod: Tasso and Venous PK Sampling

    AUCinf was calculated as AUClast + (Clast\*/kel), where AUClast is area under the plasma concentration-time profile from time zero to the time of the last quantifiable concentration (Clast). Clast is the predicted plasma concentration at the last quantifiable time point and Kel is the terminal phase rate constant. PK sampling: a) Treatment F/Test: Tasso PK micro sampling was done by CRU staff participants at the CRU up to 24 hours post-dose and by participants 48-168 hours post-dose remotely; b) Treatment G/Test: Tasso PK micro sampling was done by participants at the CRU up to 24 hours post-dose and 48-168 hours post-dose remotely. c) Treatment A/Reference: Venous PK sampling from pre-dose (0 hour) till 168 hours post-dose.

    Time frame: Pre-dose (0 hour), 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours post-dose on Day 1 of each period

  4. Cmax for Etrasimod: Tasso and Venous PK Sampling

    PK sampling: a) Treatment F/Test: Tasso PK micro sampling was done by CRU staff participants at the CRU up to 24 hours post-dose and by participants 48-168 hours post-dose remotely; b) Treatment G/Test: Tasso PK micro sampling was done by participants at the CRU up to 24 hours post-dose and 48-168 hours post-dose remotely. c) Treatment A/Reference: Venous PK sampling from pre-dose (0 hour) till 168 hours post-dose.

    Time frame: Pre-dose (0 hour), 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours post-dose on Day 1 of each period

  5. Change From Baseline in Heart Rate (HR) at 1, 2, 3, 4 ,5, 6, 8 and 24 Hours Post-dose on Day 1

    Heart rate was measured in beats per minute (beats/min). Baseline was defined as the average of triplicate electrocardiogram (ECG) HR measurements collected at pre-dose (0 hour) on Day 1 of each period.

    Time frame: Baseline; 1, 2, 3 ,4, 5, 6, 8 and 24 hours post-dose on Day 1 of each period

  6. Change From Baseline to Nadir in HR at Day 1

    Heart rate was measured in beats per minute (beats/min). Baseline was defined as the average of triplicate ECG HR measurements collected at pre-dose (0 hour) on Day 1 of each period. Nadir HR was taken as the minimum HR from all ECGs taken post-Etrasimod on day 1 of each period. If Nadir HR was attained at multiple post-dose time points on Day 1, only the latest time point was summarized.

    Time frame: Baseline; Anytime or latest time with minimum HR measurement taken post-dose on Day 1 of each period

  7. Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    An adverse event (AE) was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. TEAEs were any AEs that occurred on or after the first dose of study treatment up to 35 days post last dose of study treatment. A serious adverse event (SAE) was any untoward medical occurrence at any dose that: resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/ incapacity; resulted in congenital anomaly/birth defect.

    Time frame: Day 1 up to 35 days after last dose of study treatment (maximum up to 45 days)

  8. Number of Participants With Clinically Significant Findings in Laboratory Abnormalities

    Clinical laboratory abnormalities test criteria included, a) hematology: lymphocytes (10\^3/millimeter \[mm)\^3\]) and lymphocytes/leukocytes percentage (%) less than (\<) 0.8\* lower limit of normal (LLN), eosinophils (10\^3/mm\^3), eosinophils/leukocytes (%) and monocytes (10\^3/mm\^3) greater than (\>)1.2\* upper limit of normal (ULN); b) Urinalysis: urine glucose, ketones, urine hemoglobin and bilirubin, leukocyte esterase greater than equal to (\>=) 1. Clinical significance of laboratory abnormalities was determined by the investigator.

    Time frame: Day 1 up to 35 days after last dose of study treatment (maximum up to 45 days)

  9. Number of Participants With Clinically Significant Findings in Vital Signs

    Vital signs included blood pressure systolic and diastolic millimeter of mercury (mmHg) and pulse rate (beats/min). Clinical significance of vital signs abnormalities was determined by the investigator.

    Time frame: Day 1 up to 35 days after last dose of study treatment (maximum up to 45 days)

  10. Number of Participants With Clinically Significant Findings in Physical Examination

    A complete physical examination test included, at a minimum, head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, and gastrointestinal, musculoskeletal, and neurological systems. A brief physical examination test included, at a minimum, assessments of general appearance, the respiratory and cardiovascular systems, and participant reported symptoms. Clinical significance of physical examination abnormalities was determined by the investigator.

    Time frame: Day 1 up to 35 days after last dose of study treatment (maximum up to 45 days)

  11. Number of Participants Categorized Per Pre-defined Electrocardiogram (ECG) Findings Criteria

    ECG findings criteria for QT interval corrected using Fridericia's formula (QTcF) were as: 450 millisecond (msec) \< value less than equal (\<=) 480 msec, 480 msec \< value \<=500 msec, \>500 msec, 30 msec \<= change from baseline \<=60 msec, change from baseline \>60 msec.

    Time frame: From Baseline (Day 1) maximum up to Day 17

07

Results

Posted Mar 24, 2025

Participant flow

A total of 8 participants were enrolled in this present study.

Period 1
Participant flow — Period 1
MilestonePeriod 1: Etrasimod 2mg (Treatment F, With Practice Session)Period 2: Etrasimod 2mg (Treatment G, Without Practice Session)
Started80
Treated80
Completed70
Not completed10
Withdrew: Adverse event10
Period 2
Participant flow — Period 2
MilestonePeriod 1: Etrasimod 2mg (Treatment F, With Practice Session)Period 2: Etrasimod 2mg (Treatment G, Without Practice Session)
Started08
Treated07
Completed06
Not completed02
Withdrew: Assigned but not treated01
Withdrew: Withdrawal by subject01

Outcome measures

PrimaryArea Under the Serum Concentration-Time Profile From Time Zero to 24 Hours (AUC0-24) of Etrasimod: Tasso PK Sampling

AUC0-24 was calculated as linear/log trapezoidal method. PK sampling: a) Treatment F/Reference: Tasso PK micro sampling was done by clinical research unit (CRU) staff participants at the CRU up to 24 hours post-dose and by participants 48-168 hours post-dose remotely; b) Treatment G/Test: Tasso PK micro sampling was done by participants at the CRU up to 24 hours post-dose and 48-168 hours post-dose remotely.

Time frame:
Pre-dose (0 hour), 1, 2, 4, 6, 8, 12 and 24 hours post-dose on Day 1 of each period
Reported as:
Geometric mean · Nanogram*hour per milliliter (ng*hr/mL )
Area Under the Serum Concentration-Time Profile From Time Zero to 24 Hours (AUC0-24) of Etrasimod: Tasso PK Sampling
Nanogram*hour per milliliter (ng*hr/mL )Period 1: Etrasimod 2mg (Treatment F, With Practice Session)Period 2: Etrasimod 2mg (Treatment G, Without Practice Session)
Area Under the Serum Concentration-Time Profile From Time Zero to 24 Hours (AUC0-24) of Etrasimod: Tasso PK Sampling666.4 ± 23745.5 ± 25
Statistical analysis
  • Period 1: Etrasimod 2mg (Treatment F, With Practice Session) vs Period 2: Etrasimod 2mg (Treatment G, Without Practice Session) · Ratio of adjusted geometric means: 108.32 · 90% CI 101.20 to 115.94Ratio (Test/Reference) and its associated 90% CI were expressed as percentages.
PrimaryArea Under the Serum Concentration-Time Profile From Time 24 Hours to the Time of the Last Quantifiable Concentration (AUC24hr-last) of Etrasimod: Tasso PK Sampling

AUC24hr-last was calculated as linear/log trapezoidal method. PK sampling: a) Treatment F/Reference: Tasso PK micro sampling was done by CRU staff participants at the CRU up to 24 hours post-dose and by participants 48-168 hours post-dose remotely; b) Treatment G/Test: Tasso PK micro sampling was done by participants at the CRU up to 24 hours post-dose and 48-168 hours post-dose remotely.

Time frame:
24, 48, 72, 96, 120, 144, and 168 hours post-dose on Day 1 of each period
Reported as:
Geometric mean · ng*hr/mL
Area Under the Serum Concentration-Time Profile From Time 24 Hours to the Time of the Last Quantifiable Concentration (AUC24hr-last) of Etrasimod: Tasso PK Sampling
ng*hr/mLPeriod 1: Etrasimod 2mg (Treatment F, With Practice Session)Period 2: Etrasimod 2mg (Treatment G, Without Practice Session)
Area Under the Serum Concentration-Time Profile From Time 24 Hours to the Time of the Last Quantifiable Concentration (AUC24hr-last) of Etrasimod: Tasso PK Sampling768.4 ± 37872.1 ± 16
Statistical analysis
  • Period 1: Etrasimod 2mg (Treatment F, With Practice Session) vs Period 2: Etrasimod 2mg (Treatment G, Without Practice Session) · Ratio of adjusted geometric means: 120.41 · 90% CI 108.02 to 134.22Ratio (Test/Reference) and its associated 90% CI were expressed as percentages.
PrimaryArea Under the Serum Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUCinf) of Etrasimod: Tasso PK Sampling

AUCinf was calculated as AUClast + (Clast\*/kel), where AUClast is area under the plasma concentration-time profile from time zero to the time of the last quantifiable concentration (Clast). Clast is the predicted plasma concentration at the last quantifiable time point and Kel is the terminal phase rate constant. PK sampling: a) Treatment F/Reference: Tasso PK micro sampling was done by CRU staff participants at the CRU up to 24 hours post-dose and by participants 48-168 hours post-dose remotely; b) Treatment G/Test: Tasso PK micro sampling was done by participants at the CRU up to 24 hours post-dose and 48-168 hours post-dose remotely.

Time frame:
Pre-dose (0 hour), 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours post-dose on Day 1 of each period
Reported as:
Geometric mean · ng*hr/mL
Area Under the Serum Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUCinf) of Etrasimod: Tasso PK Sampling
ng*hr/mLPeriod 1: Etrasimod 2mg (Treatment F, With Practice Session)Period 2: Etrasimod 2mg (Treatment G, Without Practice Session)
Area Under the Serum Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUCinf) of Etrasimod: Tasso PK Sampling1503 ± 321652 ± 19
Statistical analysis
  • Period 1: Etrasimod 2mg (Treatment F, With Practice Session) vs Period 2: Etrasimod 2mg (Treatment G, Without Practice Session) · Ratio of adjusted geometric means: 115.29 · 90% CI 105.17 to 126.38Ratio (Test/Reference) and its associated 90% CI were expressed as percentages.
PrimaryMaximum Observed Concentration (Cmax) of Etrasimod: Tasso PK Sampling

PK sampling: a) Treatment F/Reference: Tasso PK micro sampling was done by CRU staff participants at the CRU up to 24 hours post-dose and by participants 48-168 hours post-dose remotely; b) Treatment G/Test: Tasso PK micro sampling was done by participants at the CRU up to 24 hours post-dose and 48-168 hours post-dose remotely.

Time frame:
Pre-dose (0 hour), 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours post-dose on Day 1 of each period
Reported as:
Geometric mean · Nanogram per milliliter (ng/mL)
Maximum Observed Concentration (Cmax) of Etrasimod: Tasso PK Sampling
Nanogram per milliliter (ng/mL)Period 1: Etrasimod 2mg (Treatment F, With Practice Session)Period 2: Etrasimod 2mg (Treatment G, Without Practice Session)
Maximum Observed Concentration (Cmax) of Etrasimod: Tasso PK Sampling40.65 ± 2644.63 ± 28
Statistical analysis
  • Period 1: Etrasimod 2mg (Treatment F, With Practice Session) vs Period 2: Etrasimod 2mg (Treatment G, Without Practice Session) · Ratio of adjusted geometric means: 106.75 · 90% CI 99.33 to 114.73Ratio (Test/Reference) and its associated 90% CI were expressed as percentages.
SecondaryAUC0-24 of Etrasimod: Tasso and Venous PK Sampling

AUC0-24 was calculated as linear/log trapezoidal method. In this outcome measure, as planned, data of participants who received Etrasimod 2 mg IR tablet (Treatment A) in C5041034 study is used for comparison. PK sampling: a) Treatment F/Test: Tasso PK micro sampling was done by CRU staff participants at the CRU up to 24 hours post-dose and by participants 48-168 hours post-dose remotely; b) Treatment G/Test: Tasso PK micro sampling was done by participants at the CRU up to 24 hours post-dose and 48-168 hours post-dose remotely; c) Treatment A/Reference: Venous PK sampling from pre-dose (0 hour) till 168 hours post-dose.

Time frame:
Pre-dose (0 hour), 1, 2, 4, 6, 8, 12 and 24 hours post-dose on Day 1 of each period
Reported as:
Geometric mean · ng*hr/mL
AUC0-24 of Etrasimod: Tasso and Venous PK Sampling
ng*hr/mLPeriod 1: Etrasimod 2mg (Treatment F, With Practice Session)Period 2: Etrasimod 2mg (Treatment G, Without Practice Session)Etrasimod 2mg IR Tablet: Treatment A, C5041034 Study
AUC0-24 of Etrasimod: Tasso and Venous PK Sampling666.4 ± 23745.5 ± 25725.8 ± 21
Statistical analysis
  • Period 1: Etrasimod 2mg (Treatment F, With Practice Session) vs Etrasimod 2mg IR Tablet: Treatment A, C5041034 Study · Ratio of adjusted geometric means: 91.80 · 90% CI 77.76 to 108.38Ratio (Test/Reference) and its associated 90% CI were expressed as percentages.
  • Period 2: Etrasimod 2mg (Treatment G, Without Practice Session) vs Etrasimod 2mg IR Tablet: Treatment A, C5041034 Study · Ratio of adjusted geometric means: 102.71 · 90% CI 86.33 to 122.19Ratio (Test/Reference) and its associated 90% CI were expressed as percentages.
SecondaryAUC24hr-last of Etrasimod: Tasso and Venous PK Sampling

AUC24hr-last was calculated as linear/log trapezoidal method. In this outcome measure, as planned, data of participants who received Etrasimod 2 mg IR tablet (Treatment A) in C5041034 study is used for comparison. PK sampling: a) Treatment F/Test: Tasso PK micro sampling was done by CRU staff participants at the CRU up to 24 hours post-dose and by participants 48-168 hours post-dose remotely; b) Treatment G/Test: Tasso PK micro sampling was done by participants at the CRU up to 24 hours post-dose and 48-168 hours post-dose remotely; c) Treatment A/Reference: Venous PK sampling from pre-dose (0 hour) till 168 hours post-dose.

Time frame:
24, 48, 72, 96, 120, 144, and 168 hours post-dose on Day 1 of each period
Reported as:
Geometric mean · ng*hr/mL
AUC24hr-last of Etrasimod: Tasso and Venous PK Sampling
ng*hr/mLPeriod 1: Etrasimod 2mg (Treatment F, With Practice Session)Period 2: Etrasimod 2mg (Treatment G, Without Practice Session)Etrasimod 2mg IR Tablet: Treatment A, C5041034 Study
AUC24hr-last of Etrasimod: Tasso and Venous PK Sampling768.4 ± 37872.1 ± 16890.1 ± 31
Statistical analysis
  • Period 1: Etrasimod 2mg (Treatment F, With Practice Session) vs Etrasimod 2mg IR Tablet: Treatment A, C5041034 Study · Ratio of adjusted geometric means: 86.34 · 90% CI 69.42 to 107.37Ratio (Test/Reference) and its associated 90% CI were expressed as percentages.
  • Period 2: Etrasimod 2mg (Treatment G, Without Practice Session) vs Etrasimod 2mg IR Tablet: Treatment A, C5041034 Study · Ratio of adjusted geometric means: 97.98 · 90% CI 76.99 to 124.70Ratio (Test/Reference) and its associated 90% CI were expressed as percentages.
SecondaryAUCinf for Etrasimod: Tasso and Venous PK Sampling

AUCinf was calculated as AUClast + (Clast\*/kel), where AUClast is area under the plasma concentration-time profile from time zero to the time of the last quantifiable concentration (Clast). Clast is the predicted plasma concentration at the last quantifiable time point and Kel is the terminal phase rate constant. PK sampling: a) Treatment F/Test: Tasso PK micro sampling was done by CRU staff participants at the CRU up to 24 hours post-dose and by participants 48-168 hours post-dose remotely; b) Treatment G/Test: Tasso PK micro sampling was done by participants at the CRU up to 24 hours post-dose and 48-168 hours post-dose remotely. c) Treatment A/Reference: Venous PK sampling from pre-dose (0 hour) till 168 hours post-dose.

Time frame:
Pre-dose (0 hour), 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours post-dose on Day 1 of each period
Reported as:
Geometric mean · ng*hr/mL
AUCinf for Etrasimod: Tasso and Venous PK Sampling
ng*hr/mLPeriod 1: Etrasimod 2mg (Treatment F, With Practice Session)Period 2: Etrasimod 2mg (Treatment G, Without Practice Session)Etrasimod 2mg IR Tablet: Treatment A, C5041034 Study
AUCinf for Etrasimod: Tasso and Venous PK Sampling1503 ± 321652 ± 191694 ± 26
Statistical analysis
  • Period 1: Etrasimod 2mg (Treatment F, With Practice Session) vs Etrasimod 2mg IR Tablet: Treatment A, C5041034 Study · Ratio of adjusted geometric means: 88.72 · 90% CI 73.10 to 107.68Ratio (Test/Reference) and its associated 90% CI were expressed as percentages.
  • Period 2: Etrasimod 2mg (Treatment G, Without Practice Session) vs Etrasimod 2mg IR Tablet: Treatment A, C5041034 Study · Ratio of adjusted geometric means: 97.54 · 90% CI 78.74 to 120.83Ratio (Test/Reference) and its associated 90% CI were expressed as percentages.
SecondaryCmax for Etrasimod: Tasso and Venous PK Sampling

PK sampling: a) Treatment F/Test: Tasso PK micro sampling was done by CRU staff participants at the CRU up to 24 hours post-dose and by participants 48-168 hours post-dose remotely; b) Treatment G/Test: Tasso PK micro sampling was done by participants at the CRU up to 24 hours post-dose and 48-168 hours post-dose remotely. c) Treatment A/Reference: Venous PK sampling from pre-dose (0 hour) till 168 hours post-dose.

Time frame:
Pre-dose (0 hour), 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours post-dose on Day 1 of each period
Reported as:
Geometric mean · ng/mL
Cmax for Etrasimod: Tasso and Venous PK Sampling
ng/mLPeriod 1: Etrasimod 2mg (Treatment F, With Practice Session)Period 2: Etrasimod 2mg (Treatment G, Without Practice Session)Etrasimod 2mg IR Tablet: Treatment A, C5041034 Study
Cmax for Etrasimod: Tasso and Venous PK Sampling40.65 ± 2644.63 ± 2843.18 ± 22
Statistical analysis
  • Period 1: Etrasimod 2mg (Treatment F, With Practice Session) vs Etrasimod 2mg IR Tablet: Treatment A, C5041034 Study · Ratio of adjusted geometric means: 94.14 · 90% CI 79.01 to 112.17Ratio (Test/Reference) and its associated 90% CI were expressed as percentages.
  • Period 2: Etrasimod 2mg (Treatment G, Without Practice Session) vs Etrasimod 2mg IR Tablet: Treatment A, C5041034 Study · Ratio of adjusted geometric means: 103.36 · 90% CI 86.04 to 124.16Ratio (Test/Reference) and its associated 90% CI were expressed as percentages.
SecondaryChange From Baseline in Heart Rate (HR) at 1, 2, 3, 4 ,5, 6, 8 and 24 Hours Post-dose on Day 1

Heart rate was measured in beats per minute (beats/min). Baseline was defined as the average of triplicate electrocardiogram (ECG) HR measurements collected at pre-dose (0 hour) on Day 1 of each period.

Time frame:
Baseline; 1, 2, 3 ,4, 5, 6, 8 and 24 hours post-dose on Day 1 of each period
Reported as:
Mean · Beats/minute
Change From Baseline in Heart Rate (HR) at 1, 2, 3, 4 ,5, 6, 8 and 24 Hours Post-dose on Day 1
Beats/minutePeriod 1: Etrasimod 2mg (Treatment F, With Practice Session)Period 2: Etrasimod 2mg (Treatment G, Without Practice Session)
Change at 1 hour-4.9 ± 3.56-3.4 ± 1.72
Change at 2 hours-10.8 ± 4.33-10.3 ± 2.75
Change at 3 hours-10.8 ± 5.44-10.9 ± 2.34
Change at 4 hours-10.8 ± 5.73-10.1 ± 3.44
Change at 5 hours-4.6 ± 4.44-2.4 ± 3.46
Change at 6 hours-7.0 ± 5.58-2.0 ± 5.92
Change at 8 hours-9.0 ± 6.82-4.9 ± 4.56
Change at 24 hours-8.4 ± 4.60-1.9 ± 5.01
SecondaryChange From Baseline to Nadir in HR at Day 1

Heart rate was measured in beats per minute (beats/min). Baseline was defined as the average of triplicate ECG HR measurements collected at pre-dose (0 hour) on Day 1 of each period. Nadir HR was taken as the minimum HR from all ECGs taken post-Etrasimod on day 1 of each period. If Nadir HR was attained at multiple post-dose time points on Day 1, only the latest time point was summarized.

Time frame:
Baseline; Anytime or latest time with minimum HR measurement taken post-dose on Day 1 of each period
Reported as:
Mean · Beats/ min
Change From Baseline to Nadir in HR at Day 1
Beats/ minPeriod 1: Etrasimod 2mg (Treatment F, With Practice Session)Period 2: Etrasimod 2mg (Treatment G, Without Practice Session)
Change From Baseline to Nadir in HR at Day 1-14.1 ± 5.14-12.1 ± 2.27
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs)

An adverse event (AE) was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. TEAEs were any AEs that occurred on or after the first dose of study treatment up to 35 days post last dose of study treatment. A serious adverse event (SAE) was any untoward medical occurrence at any dose that: resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/ incapacity; resulted in congenital anomaly/birth defect.

Time frame:
Day 1 up to 35 days after last dose of study treatment (maximum up to 45 days)
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
ParticipantsPeriod 1: Etrasimod 2mg (Treatment F, With Practice Session)Period 2: Etrasimod 2mg (Treatment G, Without Practice Session)
Number of Participants With Treatment Emergent Adverse Events (TEAEs)75
SecondaryNumber of Participants With Clinically Significant Findings in Laboratory Abnormalities

Clinical laboratory abnormalities test criteria included, a) hematology: lymphocytes (10\^3/millimeter \[mm)\^3\]) and lymphocytes/leukocytes percentage (%) less than (\<) 0.8\* lower limit of normal (LLN), eosinophils (10\^3/mm\^3), eosinophils/leukocytes (%) and monocytes (10\^3/mm\^3) greater than (\>)1.2\* upper limit of normal (ULN); b) Urinalysis: urine glucose, ketones, urine hemoglobin and bilirubin, leukocyte esterase greater than equal to (\>=) 1. Clinical significance of laboratory abnormalities was determined by the investigator.

Time frame:
Day 1 up to 35 days after last dose of study treatment (maximum up to 45 days)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Findings in Laboratory Abnormalities
ParticipantsPeriod 1: Etrasimod 2mg (Treatment F, With Practice Session)Period 2: Etrasimod 2mg (Treatment G, Without Practice Session)
Number of Participants With Clinically Significant Findings in Laboratory Abnormalities00
SecondaryNumber of Participants With Clinically Significant Findings in Vital Signs

Vital signs included blood pressure systolic and diastolic millimeter of mercury (mmHg) and pulse rate (beats/min). Clinical significance of vital signs abnormalities was determined by the investigator.

Time frame:
Day 1 up to 35 days after last dose of study treatment (maximum up to 45 days)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Findings in Vital Signs
ParticipantsPeriod 1: Etrasimod 2mg (Treatment F, With Practice Session)Period 2: Etrasimod 2mg (Treatment G, Without Practice Session)
Number of Participants With Clinically Significant Findings in Vital Signs00
SecondaryNumber of Participants With Clinically Significant Findings in Physical Examination

A complete physical examination test included, at a minimum, head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, and gastrointestinal, musculoskeletal, and neurological systems. A brief physical examination test included, at a minimum, assessments of general appearance, the respiratory and cardiovascular systems, and participant reported symptoms. Clinical significance of physical examination abnormalities was determined by the investigator.

Time frame:
Day 1 up to 35 days after last dose of study treatment (maximum up to 45 days)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Findings in Physical Examination
ParticipantsPeriod 1: Etrasimod 2mg (Treatment F, With Practice Session)Period 2: Etrasimod 2mg (Treatment G, Without Practice Session)
Number of Participants With Clinically Significant Findings in Physical Examination00
SecondaryNumber of Participants Categorized Per Pre-defined Electrocardiogram (ECG) Findings Criteria

ECG findings criteria for QT interval corrected using Fridericia's formula (QTcF) were as: 450 millisecond (msec) \< value less than equal (\<=) 480 msec, 480 msec \< value \<=500 msec, \>500 msec, 30 msec \<= change from baseline \<=60 msec, change from baseline \>60 msec.

Time frame:
From Baseline (Day 1) maximum up to Day 17
Reported as:
Count of participants · Participants
Number of Participants Categorized Per Pre-defined Electrocardiogram (ECG) Findings Criteria
ParticipantsPeriod 1: Etrasimod 2mg (Treatment F, With Practice Session)Period 2: Etrasimod 2mg (Treatment G, Without Practice Session)
450 msec < Value <= 480 msec10
480 msec < Value <= 500 msec00
Value > 500 msec00
30 msec <= Change from baseline <= 60 msec00
Change from baseline > 60 msec00

Adverse events

Collected over Day 1 up to 35 days after last dose of study treatment (maximum up to 45 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Period 1: Etrasimod 2mg (Treatment F, With Practice Session)0/8 (0%)0/8 (0%)7/8 (87.5%)
Period 2: Etrasimod 2mg (Treatment G, Without Practice Session)0/7 (0%)0/7 (0%)5/7 (71.4%)
Most frequent other events
Showing 10 of 12
Most frequent other events
EventPeriod 1: Etrasimod 2mg (Treatment F, With Practice Session)Period 2: Etrasimod 2mg (Treatment G, Without Practice Session)
Application site irritationGeneral disorders4/80/7
HeadacheNervous system disorders1/82/7
Atrioventricular block first degreeCardiac disorders2/80/7
Puncture site injuryGeneral disorders2/81/7
Abdominal painGastrointestinal disorders0/81/7
Vessel puncture site haematomaGeneral disorders0/81/7
SyncopeNervous system disorders0/81/7
Device issueProduct Issues0/81/7
Influenza like illnessGeneral disorders1/80/7
Burns second degreeInjury, poisoning and procedural complications1/80/7

Baseline characteristics

Safety analysis set (SAS) included all participants who took at least 1 dose of study intervention.

Age, Continuous
Age, Continuous(Years)All Participants: Etrasimod 2mg
Mean42.0 ± 13.70
Sex: Female, Male
Sex: Female, Male(Participants)All Participants: Etrasimod 2mg
Female4
Male4
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)All Participants: Etrasimod 2mg
Hispanic or Latino0
Not Hispanic or Latino8
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)All Participants: Etrasimod 2mg
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White8
More than one race0
Unknown or Not Reported0
08

Study locations

1 site
  • Pfizer Clinical Research Unit - Brussels
    Brussels, Bruxelles-capitale, Région DE B-1070, Belgium
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2023 to primary completion in Mar 2024, 2 months.

Results were first posted in Mar 2025, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2023
First posted
Nov 18, 2023
StartActual
Dec 20, 2023
Primary completionActual
Mar 1, 2024
CompletionActual
Mar 1, 2024
Results first posted
Mar 24, 2025
Last update
Mar 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06140290
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Nov 18, 2023
Start date
Dec 20, 2023
Primary completion
Mar 1, 2024
Completion
Mar 1, 2024
Results posted
Mar 24, 2025
Last update
Mar 24, 2025

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion